Abstract

Whether polyphenols could ameliorate inflammatory bowel disease (IBD) is still conflicting. To explore the efficacy of polyphenols as an adjuvant therapy for IBD, we conducted this systematic review and meta-analysis. Literature search was performed using PubMed, Web of Science, Scopus and Cochrane databases. Finally, 12 randomized controlled trials (RCTs) were included. In contrast to control group, curcumin treatment significantly improved clinical remission in intention-to-treat (ITT) (OR = 3.36, 95% CI: 1.09–10.37) and per-protocol (PP) analysis (OR = 5.13, 95% CI: 1.84–14.27). Meanwhile, curcumin could significantly ameliorate endoscopic remission (OR = 5.69, 95% CI: 1.28–25.27) and clinical response (OR = 4.69, 95% CI: 1.03–21.47) in PP analysis. Heterogeneity was present across the studies. In conclusions, polyphenols might be an effective adjuvant treatment for ameliorating IBD. Considering the relatively few studies included in our present study, further clinical trials are required to verify the effects of polyphenols on IBD.

摘要

多酚是否可以改善炎症性肠病（IBD）仍存在争议。为了探讨多酚作为IBD辅助治疗的功效，我们进行了系统的综述和荟萃分析。使用PubMed，Web of Science，Scopus和Cochrane数据库进行文献检索。最后，纳入了12项随机对照试验（RCT）。与对照组相比，姜黄素治疗可显着改善意向性治疗（ITT）（OR = 3.36，95％CI：1.09–10.37）和按方案（PP）分析（OR = 5.13，95％CI）的临床缓解：1.84–14.27）。同时，姜黄素可以显着改善PP分析中的内镜缓解（OR = 5.69，95％CI：1.28–25.27）和临床反应（OR = 4.69，95％CI：1.03–21.47）。研究中存在异质性。总而言之，多酚可能是改善IBD的有效佐剂。考虑到本研究中涉及的研究相对较少，因此需要进一步的临床试验来验证多酚对IBD的作用。